Tissue fibrosis is the formation of excess fibrous connective tissue in a reparative or reactive process. It is usually observed after tissue injury in the lung, liver, heart, skin, eyes, and other organs. Some fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc), can even lead to systemic progressive fibrosis and death (Varga and Abraham, 2007; Ley et al., 2011).

The development of tissue fibrosis is generally sustained and progressive. At present, almost all kinds of fibrosis have no effective treatment, and the existing treatment can only improve the quality of life or prolong the life of patients to a limited extent. Therefore, it is urgent to find new precise signaling pathways or molecules participating in tissue fibrosis, and to explore new therapeutic strategies for tissue fibrosis in order to control the progressive development of the disease and even cure the disease. The S1P (sphingosine 1-phosphate) signaling pathway has become a hot spot in the research of fibrosis mechanisms in recent years because it is involved in the development of fibrosis. In many in vitro or in vivo experiments, inhibitors of this signaling pathway have been proven to effectively inhibit the development of multiple types of fibrosis, which provides a new thought for the treatment of fibrosis and the related diseases.

In recent years, the role of lipid in intercellular signal transduction has attracted increasing attention. The sphingomyelin (SM) signaling pathway is one of the main lipids of interest, which is involved in many activities of cells and organs, including cell survival, proliferation, differentiation, and diseases, such as cancer, infection, neurodegenerative disorders, and fibrosis.

The metabolic pathway of the SM signaling pathway is shown in Figure 1. In several mammalian cells, sphingomyelinases (SMase) catalyze SM to produce ceramide (Cer), while ceramidases (CDase) catalyze Cer to produce sphingosine (Sph), and S1P can be generated by two isoforms of sphingosine kinases (SphKs), sphingosine kinase 1 (SphK1) and sphingosine kinase 2 (SphK2). At the same time, S1P can also be transformed into S1P phosphatase (S1PP) by intracellular Sph (Maceyka and Spiegel, 2014). After it is generated, S1P is secreted outside the cell by S1P transporter or degraded as ethanolamine phosphate and hexadecanal by S1P lyase (S1PL) rather than accumulating in cells under normal circumstances (Serra and Saba, 2010). S1P receptors (S1PRs, lysophospholipid receptors) are a kind of G protein coupled receptors, which have five different subtypes: S1P_1-5. S1PRs are located in different tissues. For example, S1P₁, S1P₂, and S1P₃ are widely expressed in multiple tissues; however, the expression of S1P₄ is limited to lymphatic and hematopoietic tissues, and S1P₅ is expressed in the central nervous system. Through binding to different receptors, S1P regulates many physiological or pathological processes (Xiu et al., 2015). At the same time, the expression of S1PRs is also regulated by S1P (Sanchez and Hla, 2004). S1P, as a downstream product of SM pathway, plays an important role in many life activities. This article focuses on the role of S1P and its signaling pathway, that is, the relationship between S1P, SphK, S1PRs, and S1PL, in fibrosis of the lung, liver, heart, and other tissues (summarized in Table 1) and the value of their clinical application.

In recent years, several studies have shown that some small molecular lipids, such as lysophosphatidic acid (LPA) (Zhao and Natarajan, 2013) and S1P (Nagahashi et al., 2014), are upgrade in the occurrence of diseases, such as cancer, inflammation, and tissue fibrosis. S1P is a naturally bioactive sphingolipid. S1P in plasma is mainly derived from red blood cells and activated platelets, which lack S1PL (Yatomi et al., 2001), or are phosphorylated by SphK1 (Venkataraman et al., 2006). A variety of cells, including red blood cells, platelets, macrophages, mast cells, and endothelial cells, have been confirmed to be involved in the synthesis of S1P and secret S1P into the blood (Thuy et al., 2014). S1P in blood is usually not dissociated but is closely bound up with albumin and high-density lipoprotein (HDLP) in plasma (Wilkerson et al., 2012). A study has shown that the half-life of S1P in mouse plasma is only 15 min, which indicates that it has a rapid enzymatic reaction in the plasma, and S1PP and/or S1PL plays an important role in the reaction (Nagahashi et al., 2016). S1P maintains a high level (1–2 μM) in the blood, implying that there is an efficient S1P production source in cells to maintain a high level of S1P (Salous et al., 2013). However, the concentrations of S1P in lymphatic tissues are relatively low (<0.2 μM). The concentration gradient between blood and lymph may be related to the regulation of the immune cell transportation between the body circulation and the lymphoid tissue (Donoviel et al., 2015), and the difference of concentration may be a key factor in the migration of fibroblasts and cancer cells (Cyster and Schwab, 2012).

In recent decades, functions of S1P have been determined by several studies under normal physiological conditions. In general, there are two main functions. Firstly, S1P acts as an intracellular second messenger involved in regulating cell proliferation and inhibiting apoptosis by binding to the receptor S1PRs (Pyne et al., 2016), whose function will be described in detail later in this article. Secondly, it becomes a regulator after translating out of cells regulating the cytoskeleton remodeling and cell migration, angiogenesis, and vessel maturation, the immune and lymphatic cell transport, and inflammation and malignant transformation (Hla et al., 2001; Christoffersen et al., 2011; Maceyka et al., 2012; Blaho et al., 2015; Galvani et al., 2015; Park and Im, 2017).

Sphingosine 1-phosphate is widely assumed to play a protective role in the vascular system and tissues at the physiological level, while the abnormal activation of the S1P associated signaling pathway usually leads to fibrosis, cancer, and vascular dysfunction (Delgado et al., 2012; Bhavanam et al., 2014), and S1P plays an important role in promoting fibrosis, apoptosis, inflammation, and migration in these cases (Spiegel and Milstien, 2003).

Recent studies have shown that S1P plays a crucial role in tissue fibrosis (Pyne et al., 2013; Schwalm et al., 2013), and the tissue and/or plasma concentrations of S1P are associated with a variety of fibrosis factors, including transforming growth factor β (TGF-β), platelet-derived growth factor (PDGF), and connective tissue growth factor (CTGF) (Sauer et al., 2004). Both intracellular and extracellular S1P are reported to be involved in fibrosis activities. The increase of S1P in peripheral blood is seen in a variety of fibrosis-related diseases, and the use of anti-S1P antibody to neutralize S1P can effectively reduce TGF-β-mediated collagen production (Lowe et al., 2009). In addition, a study indicates that intracellular and extracellular S1P affect cell growth and survival through different pathways (Olivera et al., 2003). Studies have also indicated that S1P-mediated autophagy may be one of the pathways in the process of fibrosis (Tatler and Jenkins, 2015), which is further described later in this article. In general, studies about the role of S1P in fibrosis have mainly focused on the effect of the secretion of key cytokines and the accumulation of extracellular matrix (ECM) after apoptosis, external chemical stimulation or hereditary diseases in cells or tissues.

Sphingosine kinase exists in a variety of cells with two types of isoforms, SphK1 and SphK2, and catalyzes the formation of S1P (Alemany et al., 2007) studies show that S1P is synthesized entirely by SphK in vivo and plays an important role in life activities (Mizugishi et al., 2005; Spiegel and Milstien, 2007). At present, the role of SphK1 in tissue fibrosis is clearer, while the studies on SphK2 are relatively few. SphK1 and SphK2 are located in different subcellular structures. SphK1 is mainly located in the cytoplasm and can be activated by a variety of agonists, including tumor necrosis factor (TNF)-α, vascular endothelial growth factor (VEGF), then transferred to the plasma membrane to convert the Sph to S1P (Taha et al., 2006). Conversely, SphK2 has the effect of inhibiting cell growth and promoting apoptosis (Igarashi et al., 2003).

Sphingosine 1-phosphate receptors are important participants in many life processes. S1P₁ plays an important role in angiogenesis in the embryonic period (Liu et al., 2000), and its function in the regulation of blood pressure in adult individuals has also been confirmed (Ryu et al., 2002), and S1P₂ is essential for the morphogenesis of zebrafish hearts (Kupperman et al., 2000). In vivo, the expression of S1PRs is regulated by many factors and cytokines. TGF-β1 has been proven to be an effective regulator to the expression of S1PRs (Chang et al., 2014). Using the supernatant of apoptotic cells to stimulate human macrophages can increase the expression level of S1P₁ in macrophages (Weichand et al., 2013). A growing body of evidence support that S1PRs play an important role in profibrosis in a variety of cells (Schwalm et al., 2013). A study, using the model of S1PR2 null mice or S1PR3 and S1PR2 double null mice, finds that the activity of Rho which is closely related to fibrosis, decreases significantly in these mouse embryonic fibroblasts (Ishii et al., 2002). After inhibiting the expression of S1PR2 and S1PR3 genes in vitro, the differentiation of myofibroblasts is inhibited, and the study also localizes S1PR2 and S1PR3 on the cell membranes (Kono et al., 2007).

In order to combine with and activate S1PRs, a large amount of S1P needs to be secreted out of the cells by the transporters. This “inside-out-signaling” process involves the synthesis and transport of S1P in the cells and the activation of different kinds of S1PRs in the autocrine and paracrine signals in mammalian cells (Takabe and Spiegel, 2014). At present, confirmed S1P transporters are mainly a variety of ATP-binding cassette (ABC) transporters, which exist in a variety of cell lines (Mitra et al., 2006; Sato et al., 2007; Takabe et al., 2010). In addition, spinster homolog 2 (Spns2) may be a special S1P transporter in different tissues (Fukuhara et al., 2012; Nagahashi et al., 2013; Nishi et al., 2014).

Sphingosine 1-phosphate lyase is a key enzyme degrading S1P into the terminal molecule: hexadecenal and ethanolamine phosphate in vivo and in vitro, thereby controlling the concentrations of S1P [9]. Many experiments have demonstrated that activation of S1PL is involved in a variety of stimulation, such as bacterial endotoxin lipopolysaccharide (LPS) and radiation exposure (Zhao et al., 2011; Billich et al., 2013).

Pulmonary fibrosis is a lung disease characterized by alveolar epithelial damage and accumulation of myofibroblasts, which are caused by a variety of factors, such as infections, inflammation, radiation exposure, and environmental pollutants (Wynn and Ramalingam, 2012). In recent years, treatment of mice with bleomycin has been used to establish a model of lung fibrosis in mice. In addition, S1PR agonists, such as fingolimod (FTY720), are also often used in the construction of in vitro models of pulmonary fibrosis, because they can induce differentiation of lung fibroblasts to myofibroblasts under prolonged stimulation (Sobel et al., 2013). We would introduce further the function of FTY720 in studies on fibrosis diseases in later part of this article.

Idiopathic pulmonary fibrosis is a chronic and progressive lung disease, characterized by alveolar epithelial cell injury and areas of type II cell hyperplasia that results in the deposition of the ECM and the differentiation of fibroblasts to myofibroblasts (Selman et al., 2001). At present, there is no effective treatment for IPF except lung transplantation, and the average of survival only 3–5 years after diagnosis (Niederman and Peters, 1998). Although the molecular and cellular mechanisms of IPF are not completely understood, several factors have been identified to be involved in the progression of IPF, such as reactive oxygen species (ROS) (Wolters et al., 2014). S1P and the signaling pathway have been recently shown to promote the pathogenesis underlying IPF. A study showed that the S1P in bronchoalveolar lavage fluid (BALF) and serum of IPF patients increased significantly compared with the control group by microarray analysis of human peripheral blood mononuclear cells. Similarly, the increased expression of S1P, SphK1, and SphK2 was negatively correlated with lung function and survival rate (Milara et al., 2012). Also, it was demonstrated that the main pathological feature of IPF patients is cell proliferation, but not apoptosis and autophagy, which may be due to the high level of S1P inhibiting the pro-apoptosis effect caused by Cer (Scarpa et al., 2013). Therefore, inhibition of the formation of S1P may be an effective treatment for reducing the proliferation of fibroblasts in IPF patients.

In addition, results provided direct evidence that SphK1 may become a new type of target for treating pulmonary fibrosis. TGF-β is an important factor during the progress of pulmonary fibrosis, and S1P signaling pathways may be involved in the process of pulmonary fibrosis promotion by TGF-β. A previous study showed that the level of S1P regulated by TGF-β is also affected by the expression of SphK1 in lung fibrosis (Kono et al., 2007). SphK1 knockout or inhibiting SphK activity can reduce the expression of S1P and the secretion of TGF-β in cells, which can also reduce bleomycin-induced mouse pulmonary fibrosis (Huang et al., 2013a). Conversely, the preconditioning of anti-TGF-β antibody can inhibit the expression of S1PL mRNA and protein induced by TGF-β in human lung fibroblasts, which indicates that, in pulmonary fibrosis, the role of S1P and its signaling pathways also depends on the level of TGF-β (Huang and Natarajan, 2015). In the TGF-β1 induced WI-38 cell fibrosis model, TGF-β1 activates SphK1 and leads to the Rho-associated myofibroblast differentiation in fibrosis (Kono et al., 2007). SphK1-deficient mice were protected against bleomycin-induced pulmonary fibrosis, and the expression of SphK1 protein increased in the lung tissues of IPF patients compared with the control group (Huang et al., 2013b).

Sphingosine 1-phosphate receptors are also closely related to the development of lung fibrosis. WI-38 cells can express S1P₁, S1P₂, and S1P₃ receptors in vitro (Urata et al., 2005). S1P can regulate pulmonary vascular permeability through S1P₁, exogenous S1P, or S1P₁ agonist activates S1P₁ to mediate cytoskeletal rearrangements, promote intercellular adhesion and tight junction formation, enhance endothelial barrier function, and promote the development of fibrosis in endothelial cells. In vitro, the S1PR agonists such as S1P, FTY720-P, and TGF-β1 do not induce the expression of the myofibroblast marker α-SMA, but all can effectively stimulate the ECM synthesis and increase the expression of CTGF and other fibrosis markers. These results indicated that, different from TGF-β1, S1PR agonists activate PI3K/Akt and ERK1/2 signals, but not Smad2/3 signals, to mediate ECM synthesis, that is, S1PR agonists stimulate human pulmonary fibrosis by stimulating S1P₁ and S1P₂ in a Smad independent pathway (Sobel et al., 2013). Further studies have shown that short-term stimulation (24 h) of S1P₁ agonists, such as FTY720 and AUY954, can enhance the integrity of the vascular endothelial barrier, reduce vascular leakage caused by injury, and protect the body. However, prolonging exposure time in these S1P₁ agonists (>7 days) can aggravate mice pulmonary fibrosis and vascular permeability, which is induced by bleomycin (Sanchez et al., 2003; Shea et al., 2010). This effect requires further confirmation in in vivo experiments.

Sphingosine 1-phosphate lyase is also involved in fibrosis development. It was demonstrated that the expression of S1PL reduces TGF-induced differentiation of fibroblasts and inhibits the expression of S1PL by knocking out the gene attenuating pulmonary fibrosis, which is induced by bleomycin in mice. On the contrary, TGF-β increases the expression of S1PL in lung fibroblasts, and this effect can be inhibited by treating cells with anti-TGF-β antibody (Huang et al., 2015). Thus, S1PL may become a novel molecule to treatment lung fibrosis.

Autophagy has also been confirmed to be related to the process of lung fibrosis. Huang et al. (2015) structured a mouse model of partial deletion of S1PL gene and found that those mice reacted more violently to bleomycin-induced pulmonary fibrosis and the expression of autophagy-related markers, LC3 and beclin 1, are reduced when their lung S1P increases; however, the overexpressed S1PL can reduce S1P and increase the level of autophagy-related markers.

In general, S1P, SphK, S1P_1,2, and S1PL have been proven to be involved in the development of pulmonary fibrosis, and the role it plays is clearer. Reducing the formation of S1P and inhibiting the activity of SphK and S1PL can effectively weaken the formation or development of fibrosis in both in vivo and in vivo, while the effects of using S1P₁ and S1P₂ agonists are related to the treatment time. At present, most of the pulmonary fibrosis diseases lack an effective treatment, and the role of S1P and its signaling pathway in pulmonary fibrosis is likely to be a potential therapeutic strategy.

Liver fibrosis is a chronic progressive liver disease characterized by the accumulation of ECM protein (Bissell, 1998). It is a precursor of cirrhosis and even liver cancer caused by chronic liver disease, multiple injuries, or dysfunctional wound healing (Kisseleva et al., 2012). The development and remission of hepatic fibrosis is believed to be a reversible process (Kisseleva et al., 2012). At present, liver transplantation is the only treatment for terminal liver disease, but it is limited by the availability of donor organs and the risk of lifetime immunosuppression (Lucey et al., 2013). Bile duct ligation (BDL) and inducing chronic low-level inflammation and necrosis of the liver by CCl4 are often used in establishing hepatic fibrosis models, and the latter is considered to be closer to the morphological and pathophysiological state of human liver fibrosis (Marques et al., 2012).

Although the research on the etiology and molecular mechanism of liver fibrosis has made great progress in the past 20 years, there is still no effective treatment strategy. There is a comprehensive source of myofibroblasts in the liver, including hepatic stellate cells (HSCs) and bone marrow-derived mesenchymal stem cells (BMSCs) (Russo et al., 2006). At the early stages of the liver fibrosis, liver injury leads to the recruitment of inflammatory cells, which release many factors causing activation of HSCs. Activated HSCs turn into a myofibroblast-like phenotype, which gain contractile, proinflammatory, and fibrogenic properties and then release proteins leading to the accumulation of ECM (Flier and Underhill, 1993; Zhang et al., 2016). PDGF is the most effective mitogen and chemotactic factor of the HSCs released factors (Pinzani, 2002). Therefore, finding a way to block HSC activation may become an effective way to search for antifibrotic drugs. Stimulating liver regeneration may be another treatment strategy for liver diseases, and the use of HSCs is considered to be one of the potential therapeutic methods. In the advanced period of liver fibrosis, liver function is destroyed and irreversible cirrhosis develops (Rippe and Brenner, 2004).

In recent years, since S1P has been found to regulate the expression level of a variety of ECM in the process of liver fibrosis, it is believed to play an important role in the process of liver fibrosis by affecting the expression of various fibrotic markers (Li et al., 2009a). HSCs have a steady state of circulation in the body, and the gradient distribution of S1P in the tissues and lymph is identified as a key regulator of the cycle (Massberg et al., 2007). An in vitro study of CCl4-induced hepatic fibrosis shows that S1P promotes the development of liver fibrosis by participating in HSCs activation and differentiation to myofibroblasts (Gonzandez-Fernandez et al., 2017). At the same time, reducing the S1P liver tissue:lymph gradient by inhibiting the migration of HSCs can also preserve the liver and reduce subsequent fibrosis, which may be a new strategy in the treatment of hepatic fibrosis in future (King et al., 2017). An animal experiment shows that BMSCs in mice migrate to the damaged liver and activate myofibroblasts induced by S1P and its receptors after the liver is damaged (Yang et al., 2012). The movement of BMSCs has also been found to be regulated by the S1P concentration gradient in the liver and bone marrow (Li et al., 2009b). Hepatic fibrosis is a sign of performance during the pathogenesis of liver cancer. Recently, a cohort study showed that S1P may be one of markers to estimate the severity of liver disease (Bartels et al., 2017).

S1P₁ and S1P₃ are considered to be the two major S1PRs that play a key role in liver fibrosis. Exogenous S1P increases the expression of SphK1 and S1P₁ and S1P₃ in human HSCs LX-2 cells (Liu et al., 2011). This phenomenon also occurs in human fibrosis liver samples (Li et al., 2011). It has been shown that a potent agonist for four of the five S1PRs (S1P_1,3-5), FTY720-P, plays a role in suppressing cell proliferation and migration in cultured HSCs by inhibiting the signal pathway between S1P and PDGF (Brunati et al., 2008). A study found that S1P-induced myofibroblasts migration from plasma to the liver injury depends on the role of S1P₃ (Li et al., 2009a). A study showed that the level of S1P in the liver is closely related to the expression of angiogenesis markers Ang1 (angiopoietin) mRNA. In addition, the S1P₁ and S1P₃ antagonists block the upregulation of Ang1 and alleviate the degree of liver fibrosis in the damaged liver (Yang et al., 2013). HuR (human embryonic lethal abnormal visual protein) is a key post-transcriptional regulator of gene expression. In recent years, increasing attention has been paid to the role of HuR in fibrosis (Bai et al., 2012; Woodhoo et al., 2012). A study has shown that there is a positive feedback mechanism between HuR and S1P₃, which can affect the vitality of BMSCs and further affect the process of fibrosis (Chang et al., 2017). However, although the expression of S1P and S1P₁ and S1P₃ is reported to play a role in promoting fibrosis in liver fibrosis models of BDL and CCl4 stimulation (Yang et al., 2013; Wang et al., 2015), S1P₁ was associated with the formation of angiogenesis and granulation tissue in another report (Yanagida and Hla, 2016), and in a study of chronic injury and cholestasis in mice, S1P₁ was found to be highly expressed in vascular endothelial cells and then reduce fibrosis by stimulating hepatic regeneration (Ding et al., 2016). These different results may be caused by different models of selection and may also be due to the removal of a variety of different kinds of liver cells, which lead to different stress responses. Therefore, in future studies, more specific experiments are needed to confirm the different roles of S1P and S1PRs in the process of fibrosis through different cells.

Studies about S1PRs and the differentiation of BMSCs are also contradictions. S1P₁ and S1P₃ are shown to be involved in the differentiation of BMSCs to myofibroblasts in mice (Yang et al., 2012). While they seem to inhibit the expression of collagen in human BMSCs (Chang et al., 2014). The above results from different laboratories may differ depending on the different species or models, but the direct mechanism of S1PRs in liver fibrosis requires further experimentation to verify, and its application in the treatment of liver fibrosis remains to be discussed.

The role of S1P₂ in the process of fibrosis is also worthy of attention. The expression of S1P₂ in the fibrosis case group and the control group is not significant in many experiments (Li et al., 2009b). However, in another study of the same model, the S1P₂ gene knockout mice or those injected with S1P₂ antagonist JTE-013 expressed low Rho kinase activity after BDL, and the expression of S1P₂ mRNA increases after the operation in the wild-type mice (Kageyama et al., 2012). In addition, a recent study confirmed the role of S1P₂ in the liver injury in a cholestasis mouse model (Wang et al., 2017). The hepatic fibrosis induced by CCl4 or dimethyl nitrosamine decreases in the S1P₂^-/- mice (Ikeda et al., 2009), and the result of a population study shows that the expression of S1P₂ decreases in patients with liver fibrosis (Li et al., 2011). These results suggest that S1P may play a role in fibrosis through S1P₂ in the process of fibrosis.

Previous studies have shown that the S1P/SphK signaling pathway is involved in liver fibrosis depending on TGF-β. A recent study provided evidence that production of collagen I is increased by SphK1 in human liver myofibroblasts after TGF treatment (Xiu et al., 2015). Recently, Melatonin it was found to be involved in protecting fibrosis in different organs, including the liver (Fernández et al., 2015). A study used CCL4 to establish a liver fibrosis model and found that melatonin treatment not only reduces the degree of fibrosis, but also inhibits the SphK1/S1P signaling pathway both in vitro and in vivo, thus confirming the hypothesis (Gonzandez-Fernandez et al., 2017).

In addition, the effect of intracellular S1P in liver fibrosis is closely related to the role of transporter Spns2 (Xiu et al., 2015). S1P may be transported out of cells by Spns2 in the process of liver fibrosis, and then combines with S1PR to promote the liver fibrosis (Sato et al., 2016). All kinds of apolipoprotein play a similar role in bile and peripheral blood, and apoM is a kind of protein mainly derived from hepatocytes, in which the spatial structure determines that its main function is to carry lipid signal molecule S1P to bind with S1P_1-5 on the membrane (Christoffersen et al., 2011; Książek et al., 2015; Hajny and Christoffersen, 2017). Research shows that apoM is the main carrier of S1P in plasma, and the secretion of apoM in the liver and other organs is correlated with the amount of S1P in the blood (Murata et al., 2000). A recent animal experiment has suggested that apoM is associated with S1P signaling pathways in liver fibrosis (Ding et al., 2016). Both S1P and apoM are involved in inducing the expression of liver receptor homologous 1 (LRH-1), suggesting that there might be a bile acid metabolic pathway between the two molecules (Pan et al., 2015). However, whether apoM is directly associated with S1P in plasma and secretion into bile needs to be explored further in the future.

In summary, the liver, as the most important metabolic organ in the body, has extensive blood flow and a complex metabolic system. Different from the lung, the concentration gradient of S1P in circulation and tissue seems to be more closely associated with liver fibrosis than the concentration of S1P, which may be due to the origin of macrophages, HSCs and BMSCs in the liver. The effect of the associated transporters in the S1P signaling pathway also contributes to the promotion of liver fibrosis. However, the role of S1PRs in liver fibrosis remains controversial and requires further study. In addition, the expression of TRAF2, melatonin, and other molecules are also involved in the regulation of liver fibrosis by S1P and its signaling pathway.

Heart failure is one of the most important health problems worldwide. According to statistics, there are approximately 23 million heart failure patients all over the world (Amp and Wilkins, 2017), and the incidence and mortality of heart failure have been gradually increasing for several decades among people aged more than 65 years (Corrao and Maggioni, 2014). Myocardial fibrosis is one of the main manifestations of the development of heart failure. It is mainly due to the secondary diseases caused by ischemia-reperfusion injury or other causes. Fibroblasts can change from static state to proliferation, migration, and secretory state in the condition of myocardial infarction, which changes the phenotype to become myofibroblasts, and then expresses contractile proteins, including α-SMA, finally leading to myocardial fibrosis (Krenning et al., 2010). At present, there is no effective treatment for myocardial fibrosis (Opie et al., 2006). Therefore, studying its development process and treatment is the key to finding a treatment for heart failure.

In the cardiovascular system, the SM signaling pathway is considered to be a signal-regulated pathway in pathological conditions. A recent review article on the role of S1P in myocardium impairment suggested that a series of signaling pathways induced by S1P is the protective factor of myocardial ischemia reperfusion and oxidative injury, and HDL plays a role in promoting it (Karliner, 2009). However, the relationship between the protective effect and myocardial fibrosis is not mentioned in the article. Interestingly, both in vitro and in vivo experiments suggest that S1P is not involved in the process of mediating the hypertrophy of myocardial cells in neonatal mice (Sekiguchi et al., 1999; Takuwa et al., 2010). However, Philippe’s study suggests that S1P mediates myocardial cell hypertrophy in mice through S1P₁ (Robert et al., 2001). A study has shown that S1P plays an important role in the regulation of cardiac fibroblast migration and proinflammatory response in myocardial hypoxia (Kacimi et al., 2007). Relaxin (RLX), a kind of peptide hormone causing a physiological cardiac effect, is the key regulation factor of ECM remodeling in many tissues (Et et al., 2008). A study using immature primary cardiac myocytes isolated from neonatal mice and mice heart myofibroblasts H9C2 found that RLX could mediate SM metabolism, SphK1 activation, and the production of S1P in cardiac myocytes. Meanwhile, the production of S1P mediated by RLX is the key to ECM remodeling in cardiac myocytes, and it provides a new therapeutic strategy for preventing cardiac fibrosis and promoting myocardial regeneration (Frati et al., 2015). However, studies researching the role of S1P in cardiac hypertrophy and fibrosis remain insufficient in both in vitro and in vivo, and the models are not consistent, and the model, which uses S1P or the interrelated molecules to induce myocardial hypertrophy and fibrosis directly, is likely to change the metabolic rate of other molecules in the pathway, resulting in incorrect judgment of the effects of S1P. Thereby, these conclusions suggest that using S1P and some molecules in its pathway may be a potential method for the treatment of myocardial hypertrophy and fibrosis, while, due to the contrary results, the mechanism still needs to be further confirmed in in vivo experiments, and the correlation between these phenomena and human heart fibrosis warrants further exploration.

The expression of SphK1 in cardiac fibroblasts can affect the degeneration and fibrosis of cardiomyocytes. In vivo study showed that SPHK1-transgenic mice present myocardial degeneration and fibrosis at high levels of SphK1 (SphK1 activity increased 20 times), while this is not observed at lower SphK1 levels (SphK1 activity increased five times) (Takuwa et al., 2010). However, there is an opposite conclusion: the expression of SphK1 in cardiac fibroblasts is much higher than that in cardiac myocytes. Under normal conditions, SphK1 is necessary for the proliferation of cardiac fibroblasts, but in the case of myocardial hypoxia, SphK1 plays an anti-inflammatory role and inhibits the occurrence of cardiac fibrosis. Therefore, it plays a dual regulatory role in cardiac physiology and pathology (Kacimi et al., 2007). The above two studies have shown that SphK1 does play a regulatory role in the process of cardiac fibrosis. However, this effect may be related to the activity and expression of SphK1. Therefore, the mechanisms of SphK1 in cardiac fibrosis require further study.

S1P₁, S1P₂, and S1P₃ are expressed in the heart. There are differences in the distribution of different subtypes of S1PRs in different types of cardiac cells: the main distribution of S1PR in cardiomyocytes is S1P₁, while the expression of S1P₂ and S1P₃ are low (Zhang et al., 2007; Landeen et al., 2008), and S1P₃ is mainly distributed in fibroblasts (Landeen et al., 2007). A study shows that S1PRs can regulate the ion channel and mediate myocardial self-protection through ischemic preconditioning, so it is a key molecule to regulate the function of the myocardium (Keul et al., 2016). A mouse experiment shows that the expression of S1P₁ is upregulated during myocardial hypertrophy and could be overexpressed in interleukin (IL)-6 secretion depending on the Ang II-AT1, causing cardiac hypertrophy and fibrosis, and affecting the systolic function of the heart. However, this phenomenon occurs only in the proliferative fibroblasts/myocytes of the mouse heart, but not in the cardiomyocytes (Ohkura et al., 2017). In vivo, the activation of S1P₂ and S1P₃ can weaken the ischemia-reperfusion injury of myocardium. The mechanism may be that S1P can affect ventricular fibrosis through S1P₃, and then mediate fibroblast differentiation into myofibroblasts, which may be a therapeutic strategy to treat fibrosis after cardiac physiology and pathology injury (Means et al., 2007; Benamer et al., 2011). Additionally, knocking out S1P₃ in the heart cells can inhibit the fibrosis in mice with high expression of SphK1 through a Rho- and Smad3-dependent signaling pathway (Takuwa et al., 2010). FTY720 can also reduce the formation of myocardial fibrosis by inhibiting oxygen free radicals to produce strong anti-inflammatory and antioxidant properties, thus reducing the death of cardiomyocytes (Aytan et al., 2016). A study using the heart transplantation mouse model suggests that FTY720 is an effective ischemic preconditioning agent, which can reduce apoptosis, inflammation, oxidative stress, and myocardial fibrosis in the model (Ahmed et al., 2017).

In recent years, the role of S1P in the relationship between autophagy and myocardial damage has become a topic of concern. As in other tissues, autophagy after myocardial damage is beneficial to the organism in most cases, but in some cases, it also causes damage to the organism. A study suggests that autophagy-related survival is regulated by SphK1 to some extent, while autophagy-related deaths are regulated by Cer (Lavieu et al., 2007).

In a comprehensive sense, S1P, S1PR, and SphK are related to the expression of several factors in many interrelated fibrotic pathways in the process of cardiac fibrosis and play a role in the pathogenesis and development of fibrosis together. However, the molecular mechanism of the relationship between S1P and cardiac fibrosis is unclear, as is the promotion or inhibition of cardiac fibrosis in different conditions. Therefore, whether these molecules in the pathway can be used in future as a target for the treatment of cardiac fibrosis still require further study in vitro and in vivo.

Diabetic nephropathy, which usually leads to renal fibrosis, begins with hyperglycemia, which subsequently generates glucotoxicity in renal tubular epithelial cells. Later, like other fibrosis diseases, inflammatory cells are recruited and activated to produce a large number of inflammatory factors, such as monocyte chemoattractant protein 1 (MCP1) and TGF-βs, which are soon released into the interstitium, and fibrosis-related signal pathways are activated, resulting in the positive feedback to promote the production and accumulation of ECM. In particular, extracellular growth factors can stimulate the paracrine effect in renal fibrosis (Lehmann and Schleicher, 2000). A study has shown that S1P signaling may take part in the development of fibrosis in diabetic nephropathy (Yaghobian et al., 2016). Living in the environment of hyperglycemia and oxidative stress for a long time activate SphK1 and increase S1P synthesis (Wang et al., 2005). Glucose stimulation increased the level of S1P in pancreatic islet cells under the action of SphK2, but the levels of Cer and Sph remained unchanged (Boslem et al., 2012; Stanford et al., 2012). A further study has shown that FTY720 selectively inhibits lymphocyte migration and alleviates ischemia-reperfusion injury after renal fibrosis by reducing the release of ECM and finally reduces the progression of glomerulosclerosis (Delbridge et al., 2007).

Gluteal muscle contracture (GMC) is also a chronic fibrotic disease caused by multiple etiologies, which is characterized by proliferation of fibroblasts and accumulation of collagen in the ECM of muscles (Zhao et al., 2010). A recent study provided evidence that the level of S1P increased in the muscles of patients with GMC, and exogenous S1P stimulation can promote the proliferation of contraction band (CB) fibroblasts in a dose- and time-dependent manner, and also promote the expression of α-SMA, collagen, TGF-β1, and PAI-1 at mRNA and protein levels, which indicates that S1P plays several roles in the development of GMC (Zhao et al., 2013). In addition, the SphK1/S1PR signaling pathway is also involved in the process of TGF-β-mediated skeletal muscle fibroblasts transforming into myofibroblasts and plays a role in profibrosis (Cencetti et al., 2010).

Sphingosine 1-phosphate and the related signaling pathway are also involved in ocular fibrosis. It can stimulate retinal pigmented epithelial cells converting into fibroblast-like cells. At the same time, S1P increases two markers of fibrosis, PAI-1 and HSP47 (Swaney et al., 2008). Intravenous anti-S1P monoclonal antibody can inhibit choroid neovascularization and collagen deposition under the retina, suggesting that extracellular S1P plays an important role in ocular fibrosis (Caballero et al., 2009). Therefore, the use of anti-S1P antibodies may be a therapeutic strategy for ocular fibrosis and exudative age-related macular degeneration by inhibiting the formation of profibrosis factors, angiogenesis, and retinal fibrosis, but research is still lacking regarding the role of S1PRs.

Dermal fibroblasts and myofibroblasts play an important role in the repair and remodeling of wounds. Due to the role of S1P and S1PRs in cell migration and their profibrosis effects, a study has suggested that they may have important clinical implications in trauma repair and abnormal wound healing (Watterson et al., 2007). S1P₁ and S1P₃ have been shown to cooperate with TLR4 to promote the secretion of pro-inflammatory cytokines in endothelial and epithelial cells (Eskan et al., 2008). An in vitro experiment demonstrated that TLR activation and S1P stimulation together regulate the inflammatory response in normal human dermal fibroblasts, which has been shown to induce pro-inflammatory cytokine production and myofibroblast differentiation as well as cell migration (Hamidi et al., 2014).

In general, S1P is up-regulated in the development of kidney, gluteal, ocular, and dermal fibrosis, and is thought to play a role in promoting fibrosis by interacting with other molecules, such as inflammatory factors, in these tissue fibrosis.